September 1, 2015
So obesity specialists were ecstatic when the FDA gave the OK, in rapid succession, to Belviq and Qsymia in 2012. Then came Contrave last September. Those three drugs, in pill form, were followed by the injectable Saxenda, approved last December. "Having four more options is a wonderful start," says Martin Binks, secretary/treasurer of The Obesity Society and an associate professor of nutritional sciences at Texas Tech University in Lubbock. All are intended for use in the obese – people with a BMI of 30 (say, 203 pounds at 5'9") or more – or in a subset of overweight people who also have a problem such as or high blood pressure.
Read the story here.